Breaking News
Sort by:
Top Post
Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an 'Off-The-Shelf' Cancer Immunotherapy Developed using Nouscom's Proprietary Viral Vector Platform
Nouscom, a clinical stage immuno-oncology company developing both off-the-shelf and personalized cancer neoantigen immunotherapies, today […]
ADA Names Charles D. Henderson as New Chief Executive Officer
The American Diabetes Association® (ADA), the nation’s leading voluntary health organization fighting to bend the curve […]
Targovax Announces Clinical Collaboration With Agenus for Upcoming ONCOS-102 Phase 2 Melanoma Trial
Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid […]
Targovax and Oslo University Hospital Announce Collaboration To Test TG Mutant RAS Vaccination in Multiple Myeloma
Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid […]
Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris (ravulizumab-cwvz) achieved a statistically […]
Quell Therapeutics and Cellistic™ Enter a Strategic Collaboration to Develop an iPSC-derived Allogeneic T-regulatory (Treg) Cell Therapy Platform
Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious […]
Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics
Epitopea, a transatlantic cancer immunotherapeutics company and global leader in exploiting a new class of […]
Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, […]
CardioRenal Raises €3.3 million
CardioRenal, a company specialized in improving treatment at home for patients with severe chronic kidney […]
Accord BioPharma Announces U.S. Launch for CAMCEVI™ (Leuprolide) Injection Emulsion for the Treatment of Advanced Prostate Cancer in Adults
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more